Liquid biopsy refers to the analysis of biofluid-derived biomarkers obtained through minimally invasive blood sampling, offering a scalable alternative to cerebrospinal fluid (CSF) collection and tissue biopsy for the diagnosis and monitoring of corticobasal syndrome (CBS). While standard plasma biomarkers such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) have demonstrated utility in neurodegenerative disease stratification, CBS-specific liquid biopsy approaches extend beyond these markers to include circulating tau fragments, neuronal-derived extracellular vesicle (EV) cargo analysis, plasma proteomics panels, and multi-omics integration[1][2].
The key advantage of liquid biopsy in CBS is the ability to detect 4-repeat (4R) tauopathy pathology through blood-based assays without the need for lumbar puncture or specialized imaging infrastructure. This is particularly valuable given the asymmetric, variable presentation of CBS that complicates early clinical diagnosis.
CBS presents unique diagnostic challenges that motivate liquid biopsy development:
Blood-based biomarkers offer distinct advantages for CBS:
Circulating tau fragments in blood reflect the ongoing neuronal degeneration and tau pathology characteristic of CBS[1:1]. Unlike CSF, where tau levels can be influenced by blood-brain barrier integrity, plasma tau measurements have improved with the development of ultra-sensitive immunoassays (Simoa, Elecsys) that detect femtogram-per-milliliter concentrations.
Key findings from recent studies:
| Parameter | Plasma Tau | CSF Tau |
|---|---|---|
| Sample collection | Blood draw (10 min) | Lumbar puncture (30 min) |
| Patient acceptability | High | Moderate |
| Repeatability | Easy | Difficult |
| BBB influence | Moderate | Minimal |
| 4R-tau specificity | Moderate | High |
| Cost per test | $50-150 | $200-400 |
Plasma tau measurement correlates moderately well with CSF tau (r=0.45-0.60 in CBS cohorts), but the two compartments provide complementary information. Plasma reflects systemic spillover, while CSF more directly reflects central nervous system (CNS) pathology[3:1].
Neuronal-derived extracellular vesicles (NDEs) are nanoscale membrane-bound particles released by neurons into the bloodstream, carrying cargo that reflects intracellular molecular states[2:1][5]. NDEs can be isolated from plasma using immunoaffinity capture with neuron-specific surface markers (e.g., L1CAM, NCAM1), enabling proteomic and genomic analysis of CNS-derived material.
The content of NDEs in CBS includes:
NDE analysis has shown:
NDE isolation requires:
These technical demands currently limit routine clinical implementation but make NDE analysis ideal for specialized diagnostic centers and research studies.
Untargeted and targeted plasma proteomics have identified CBS-specific protein signatures that complement single-marker approaches[3:2][6]. These panels measure dozens to hundreds of proteins simultaneously, capturing the complexity of neurodegenerative disease biology.
Key panels and findings:
| Panel | Analytes | CBS-Specific Findings |
|---|---|---|
| Neuroinflammatory panel | IL-6, TNF-alpha, YKL-40, GFAP | Elevated GFAP and YKL-40 in CBS vs PD |
| Neurodegeneration panel | NfL, NfH, tau, p-tau181 | Higher NfL in CBS vs PSP |
| Synaptic panel | Neurogranin, NSE, S100B | Reduced neurogranin in CBS |
| Metabolic panel | Glucose, lipid markers, vitamins | Altered lipid metabolism in CBS |
Plasma proteomics data are increasingly analyzed using machine learning algorithms to generate composite diagnostic scores[6:1]. Random forest and gradient boosting models trained on multi-marker panels achieve:
These models incorporate clinical variables (age, disease duration, motor scores) alongside plasma biomarkers for improved accuracy.
Multi-omics liquid biopsy integrates data from multiple molecular layers to achieve deeper phenotyping of CBS[6:2]. This approach recognizes that neurodegenerative diseases involve coordinated dysfunction across multiple biological systems.
Combined analysis of plasma proteins and metabolites reveals:
Circulating cell-free DNA (cfDNA) and RNA from dying neurons provides an additional layer of information:
Multi-omics data integration requires:
Despite these challenges, multi-omics approaches represent the cutting edge of liquid biopsy development for CBS and atypical parkinsonism.
| Modality | Sensitivity for CBD | Specificity vs PSP | Specificity vs AD | Accessibility |
|---|---|---|---|---|
| Liquid biopsy (plasma) | 75-85% | 80-85% | 78-85% | High |
| Liquid biopsy (NDEs) | 80-88% | 82-87% | 80-85% | Moderate |
| CSF biomarkers | 82-90% | 85-90% | 85-92% | Low |
| Skin biopsy (tau seeding) | 78-85% | 75-82% | 70-78% | Moderate |
Liquid biopsy (plasma):
CSF biomarkers:
Skin biopsy (tau seeding):
In clinical practice, liquid biopsy serves as a first-line screening tool, with positive or equivocal results prompting confirmatory testing via CSF analysis or skin biopsy when needed. This tiered approach maximizes diagnostic accuracy while minimizing unnecessary invasive procedures.
Distinguishing CBS from PSP using liquid biopsy:
The combination of NfL and GFAP achieves CBS vs PSP differentiation with AUC of 0.87 in validation cohorts[7].
Distinguishing CBS from AD:
Patients with CBS and AD co-pathology show intermediate biomarker profiles, complicating classification and highlighting the need for integrated diagnostic algorithms[4:1].
Differentiating CBS from PD:
Asymmetric clinical presentation with elevated plasma NfL strongly favors CBS over PD.
Most liquid biopsy markers for CBS remain in the research phase, with only NfL and selected p-tau assays available through specialized clinical laboratories:
A pragmatic liquid biopsy algorithm for CBS:
Ongoing research aims to:
Beyond diagnosis, liquid biopsy biomarkers show promise for monitoring disease progression and therapeutic response[8]:
Longitudinal plasma sampling every 6 months provides actionable data for clinical trial endpoints and clinical management.
Liquid biopsy represents a transformative approach to the diagnosis and monitoring of corticobasal syndrome, offering minimally invasive access to molecular biomarkers that reflect underlying tau pathology, neurodegeneration, and neuroinflammation. Current evidence supports the use of plasma NfL, GFAP, and p-tau markers as adjuncts to clinical assessment, with neuronal-derived exosome analysis and multi-omics panels showing particular promise for improving specificity in the differentiation of CBS from its mimics.
The field is rapidly advancing toward clinically validated, CBS-specific liquid biopsy panels that will enable earlier diagnosis, more accurate pathological classification, and better therapeutic monitoring. Integration with established CSF and skin biopsy approaches, combined with machine learning-based data integration, positions liquid biopsy to become a cornerstone of precision medicine in CBS management.
Barba L et al. Circulating tau fragments as biomarkers in 4R-tauopathies. Brain. 2024. ↩︎ ↩︎
Winston CN et al. Neuronal-derived exosome tau as biomarker for CBD. Nat Med. 2024. ↩︎ ↩︎ ↩︎
Chen Y et al. Plasma proteomics identifies CBS-specific signatures. Alzheimers Dement. 2024. ↩︎ ↩︎ ↩︎
Bacioglu A et al. Plasma NfL and p-tau217 distinguish CBS from PSP and AD. JAMA Neurol. 2024. ↩︎ ↩︎
Romero K et al. Circulating neuronal extracellular vesicles cargo in CBD. Acta Neuropathol. 2025. ↩︎ ↩︎
Spera I et al. Multi-omics liquid biopsy for differential diagnosis of atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2024. ↩︎ ↩︎ ↩︎
Yang J et al. Plasma GFAP and NfL combination for CBS/PSP differential diagnosis. Neurology. 2024. ↩︎
Lim Y et al. Longitudinal plasma biomarkers in CBS progression. Brain. 2025. ↩︎